Cargando…

Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from neuromuscular respiratory failure, typically within 3 to 5 years. There is a stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Khleifat, Ahmad, Iacoangeli, Alfredo, Jones, Ashley R., van Vugt, Joke J. F. A., Moisse, Matthieu, Shatunov, Aleksey, Zwamborn, Ramona A. J., van der Spek, Rick A. A., Cooper-Knock, Johnathan, Topp, Simon, van Rheenen, Wouter, Kenna, Brendan, Van Eijk, Kristel R., Kenna, Kevin, Byrne, Ross, López, Victoria, Opie-Martin, Sarah, Vural, Atay, Campos, Yolanda, Weber, Markus, Smith, Bradley, Fogh, Isabella, Silani, Vincenzo, Morrison, Karen E., Dobson, Richard, van Es, Michael A., McLaughlin, Russell L., Vourc’h, Patrick, Chio, Adriano, Corcia, Philippe, de Carvalho, Mamede, Gotkine, Marc, Panades, Monica Povedano, Mora, Jesus S., Shaw, Pamela J., Landers, John E., Glass, Jonathan D., Shaw, Christopher E., Basak, Nazli, Hardiman, Orla, Robberecht, Wim, Van Damme, Philip, van den Berg, Leonard H., Veldink, Jan H., Al-Chalabi, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799999/
https://www.ncbi.nlm.nih.gov/pubmed/36589292
http://dx.doi.org/10.3389/fncel.2022.1050596
_version_ 1784861200221208576
author Al Khleifat, Ahmad
Iacoangeli, Alfredo
Jones, Ashley R.
van Vugt, Joke J. F. A.
Moisse, Matthieu
Shatunov, Aleksey
Zwamborn, Ramona A. J.
van der Spek, Rick A. A.
Cooper-Knock, Johnathan
Topp, Simon
van Rheenen, Wouter
Kenna, Brendan
Van Eijk, Kristel R.
Kenna, Kevin
Byrne, Ross
López, Victoria
Opie-Martin, Sarah
Vural, Atay
Campos, Yolanda
Weber, Markus
Smith, Bradley
Fogh, Isabella
Silani, Vincenzo
Morrison, Karen E.
Dobson, Richard
van Es, Michael A.
McLaughlin, Russell L.
Vourc’h, Patrick
Chio, Adriano
Corcia, Philippe
de Carvalho, Mamede
Gotkine, Marc
Panades, Monica Povedano
Mora, Jesus S.
Shaw, Pamela J.
Landers, John E.
Glass, Jonathan D.
Shaw, Christopher E.
Basak, Nazli
Hardiman, Orla
Robberecht, Wim
Van Damme, Philip
van den Berg, Leonard H.
Veldink, Jan H.
Al-Chalabi, Ammar
author_facet Al Khleifat, Ahmad
Iacoangeli, Alfredo
Jones, Ashley R.
van Vugt, Joke J. F. A.
Moisse, Matthieu
Shatunov, Aleksey
Zwamborn, Ramona A. J.
van der Spek, Rick A. A.
Cooper-Knock, Johnathan
Topp, Simon
van Rheenen, Wouter
Kenna, Brendan
Van Eijk, Kristel R.
Kenna, Kevin
Byrne, Ross
López, Victoria
Opie-Martin, Sarah
Vural, Atay
Campos, Yolanda
Weber, Markus
Smith, Bradley
Fogh, Isabella
Silani, Vincenzo
Morrison, Karen E.
Dobson, Richard
van Es, Michael A.
McLaughlin, Russell L.
Vourc’h, Patrick
Chio, Adriano
Corcia, Philippe
de Carvalho, Mamede
Gotkine, Marc
Panades, Monica Povedano
Mora, Jesus S.
Shaw, Pamela J.
Landers, John E.
Glass, Jonathan D.
Shaw, Christopher E.
Basak, Nazli
Hardiman, Orla
Robberecht, Wim
Van Damme, Philip
van den Berg, Leonard H.
Veldink, Jan H.
Al-Chalabi, Ammar
author_sort Al Khleifat, Ahmad
collection PubMed
description BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from neuromuscular respiratory failure, typically within 3 to 5 years. There is a strong genetic contribution to ALS risk. In 10% or more, a family history of ALS or frontotemporal dementia is obtained, and the Mendelian genes responsible for ALS in such families have now been identified in about 50% of cases. Only about 14% of apparently sporadic ALS is explained by known genetic variation, suggesting that other forms of genetic variation are important. Telomeres maintain DNA integrity during cellular replication, differ between sexes, and shorten naturally with age. Sex and age are risk factors for ALS and we therefore investigated telomere length in ALS. METHODS: Samples were from Project MinE, an international ALS whole genome sequencing consortium that includes phenotype data. For validation we used donated brain samples from motor cortex from people with ALS and controls. Ancestry and relatedness were evaluated by principal components analysis and relationship matrices of DNA microarray data. Whole genome sequence data were from Illumina HiSeq platforms and aligned using the Isaac pipeline. TelSeq was used to quantify telomere length using whole genome sequence data. We tested the association of telomere length with ALS and ALS survival using Cox regression. RESULTS: There were 6,580 whole genome sequences, reducing to 6,195 samples (4,315 from people with ALS and 1,880 controls) after quality control, and 159 brain samples (106 ALS, 53 controls). Accounting for age and sex, there was a 20% (95% CI 14%, 25%) increase of telomere length in people with ALS compared to controls (p = 1.1 × 10(−12)), validated in the brain samples (p = 0.03). Those with shorter telomeres had a 10% increase in median survival (p = 5.0×10(−7)). Although there was no difference in telomere length between sporadic ALS and familial ALS (p=0.64), telomere length in 334 people with ALS due to expanded C9orf72 repeats was shorter than in those without expanded C9orf72 repeats (p = 5.0×10(−4)). DISCUSSION: Although telomeres shorten with age, longer telomeres are a risk factor for ALS and worsen prognosis. Longer telomeres are associated with ALS.
format Online
Article
Text
id pubmed-9799999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97999992022-12-30 Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data Al Khleifat, Ahmad Iacoangeli, Alfredo Jones, Ashley R. van Vugt, Joke J. F. A. Moisse, Matthieu Shatunov, Aleksey Zwamborn, Ramona A. J. van der Spek, Rick A. A. Cooper-Knock, Johnathan Topp, Simon van Rheenen, Wouter Kenna, Brendan Van Eijk, Kristel R. Kenna, Kevin Byrne, Ross López, Victoria Opie-Martin, Sarah Vural, Atay Campos, Yolanda Weber, Markus Smith, Bradley Fogh, Isabella Silani, Vincenzo Morrison, Karen E. Dobson, Richard van Es, Michael A. McLaughlin, Russell L. Vourc’h, Patrick Chio, Adriano Corcia, Philippe de Carvalho, Mamede Gotkine, Marc Panades, Monica Povedano Mora, Jesus S. Shaw, Pamela J. Landers, John E. Glass, Jonathan D. Shaw, Christopher E. Basak, Nazli Hardiman, Orla Robberecht, Wim Van Damme, Philip van den Berg, Leonard H. Veldink, Jan H. Al-Chalabi, Ammar Front Cell Neurosci Neuroscience BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from neuromuscular respiratory failure, typically within 3 to 5 years. There is a strong genetic contribution to ALS risk. In 10% or more, a family history of ALS or frontotemporal dementia is obtained, and the Mendelian genes responsible for ALS in such families have now been identified in about 50% of cases. Only about 14% of apparently sporadic ALS is explained by known genetic variation, suggesting that other forms of genetic variation are important. Telomeres maintain DNA integrity during cellular replication, differ between sexes, and shorten naturally with age. Sex and age are risk factors for ALS and we therefore investigated telomere length in ALS. METHODS: Samples were from Project MinE, an international ALS whole genome sequencing consortium that includes phenotype data. For validation we used donated brain samples from motor cortex from people with ALS and controls. Ancestry and relatedness were evaluated by principal components analysis and relationship matrices of DNA microarray data. Whole genome sequence data were from Illumina HiSeq platforms and aligned using the Isaac pipeline. TelSeq was used to quantify telomere length using whole genome sequence data. We tested the association of telomere length with ALS and ALS survival using Cox regression. RESULTS: There were 6,580 whole genome sequences, reducing to 6,195 samples (4,315 from people with ALS and 1,880 controls) after quality control, and 159 brain samples (106 ALS, 53 controls). Accounting for age and sex, there was a 20% (95% CI 14%, 25%) increase of telomere length in people with ALS compared to controls (p = 1.1 × 10(−12)), validated in the brain samples (p = 0.03). Those with shorter telomeres had a 10% increase in median survival (p = 5.0×10(−7)). Although there was no difference in telomere length between sporadic ALS and familial ALS (p=0.64), telomere length in 334 people with ALS due to expanded C9orf72 repeats was shorter than in those without expanded C9orf72 repeats (p = 5.0×10(−4)). DISCUSSION: Although telomeres shorten with age, longer telomeres are a risk factor for ALS and worsen prognosis. Longer telomeres are associated with ALS. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9799999/ /pubmed/36589292 http://dx.doi.org/10.3389/fncel.2022.1050596 Text en Copyright © 2022 Al Khleifat, Iacoangeli, Jones, van Vugt, Moisse, Shatunov, Zwamborn, van der Spek, Cooper-Knock, Topp, van Rheenen, Kenna, Van Eijk, Kenna, Byrne, López, Opie-Martin, Vural, Campos, Weber, Smith, Fogh, Silani, Morrison, Dobson, van Es, McLaughlin, Vourc’h, Chio, Corcia, de Carvalho, Gotkine, Panades, Mora, Shaw, Landers, Glass, Shaw, Basak, Hardiman, Robberecht, Van Damme, van den Berg, Veldink and Al-Chalabi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Al Khleifat, Ahmad
Iacoangeli, Alfredo
Jones, Ashley R.
van Vugt, Joke J. F. A.
Moisse, Matthieu
Shatunov, Aleksey
Zwamborn, Ramona A. J.
van der Spek, Rick A. A.
Cooper-Knock, Johnathan
Topp, Simon
van Rheenen, Wouter
Kenna, Brendan
Van Eijk, Kristel R.
Kenna, Kevin
Byrne, Ross
López, Victoria
Opie-Martin, Sarah
Vural, Atay
Campos, Yolanda
Weber, Markus
Smith, Bradley
Fogh, Isabella
Silani, Vincenzo
Morrison, Karen E.
Dobson, Richard
van Es, Michael A.
McLaughlin, Russell L.
Vourc’h, Patrick
Chio, Adriano
Corcia, Philippe
de Carvalho, Mamede
Gotkine, Marc
Panades, Monica Povedano
Mora, Jesus S.
Shaw, Pamela J.
Landers, John E.
Glass, Jonathan D.
Shaw, Christopher E.
Basak, Nazli
Hardiman, Orla
Robberecht, Wim
Van Damme, Philip
van den Berg, Leonard H.
Veldink, Jan H.
Al-Chalabi, Ammar
Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title_full Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title_fullStr Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title_full_unstemmed Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title_short Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
title_sort telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799999/
https://www.ncbi.nlm.nih.gov/pubmed/36589292
http://dx.doi.org/10.3389/fncel.2022.1050596
work_keys_str_mv AT alkhleifatahmad telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT iacoangelialfredo telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT jonesashleyr telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vanvugtjokejfa telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT moissematthieu telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT shatunovaleksey telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT zwambornramonaaj telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vanderspekrickaa telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT cooperknockjohnathan telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT toppsimon telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vanrheenenwouter telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT kennabrendan telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vaneijkkristelr telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT kennakevin telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT byrneross telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT lopezvictoria telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT opiemartinsarah telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vuralatay telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT camposyolanda telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT webermarkus telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT smithbradley telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT foghisabella telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT silanivincenzo telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT morrisonkarene telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT dobsonrichard telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vanesmichaela telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT mclaughlinrusselll telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vourchpatrick telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT chioadriano telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT corciaphilippe telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT decarvalhomamede telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT gotkinemarc telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT panadesmonicapovedano telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT morajesuss telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT shawpamelaj telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT landersjohne telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT glassjonathand telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT shawchristophere telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT basaknazli telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT hardimanorla telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT robberechtwim telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vandammephilip telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT vandenbergleonardh telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT veldinkjanh telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata
AT alchalabiammar telomerelengthanalysisinamyotrophiclateralsclerosisusinglargescalewholegenomesequencedata